Thank you for taking the time to learn about our research program! Our work primarily focuses on understanding the mechanisms underlying chronic stress, trauma, depression, and suicidality. We place particular emphasis on the glutamatergic system including neuroenergetics (the study of energy demands in brain function) and the behavioral and neural effects of glutamate-based experimental psychopharmacologic agents (e.g., ketamine). We are also interested in glial cells because of their critical role in glutamate neurotransmission, synaptic plasticity, and neuroenergetics.
The pathophysiologic effects of trauma and chronic stress on the tripartite glutamatergic synapse are believed to underlie various biological abnormalities observed across many neuropsychiatric disorders. However, the development of truly novel drugs for stress-based psychiatric disorders and related symptoms (e.g., PTSD, depression, suicidality), directly targeting the negative effects of chronic stress, have been hampered by the limited understanding of the neural mechanisms underlying these distress pathologies in humans, and by the lack of reliable biological assays of treatment target validation. Overall, our research program is focusing on establishing biomarkers of target engagement and target validation of distress pathology. We are pursuing this line of research through cross-sectional investigations as well as longitudinal pharmacological challenges, in combination with state-of-the-art multimodal neuroimaging approaches. It is our hope that our work can advance the field’s understanding of neural mechanisms underlying stress-related psychopathology and through this inform improved prevention, diagnostics, risk identification, and treatment including novel drug development.